Cambridge Healthtech Institute第一届

Drug Discovery for Rare Diseases

( 罕见疾病疗法的开发 )

聚焦于基因体标的、蛋白质体标的、药物形式的论坛

2018年3月28日 | Boston Marriott Cambridge | 马萨诸塞州剑桥

罕见疾病是影响非常少数人的疾病,近年来其重要度及关注程度逐渐提升。美国国家卫生研究院指出,现在世界上有将近7,000种罕见疾病的存在,超过2,500万美国人罹患这些疾病,而约有80%的罕见疾病被认为与基因有关。本论坛以罕见疾病疗法的开发为主题,开发各种罕见疾病疗法的主要研究人员、临床医师、企业干部、专家将聚集于此,针对新创药标的、正在研究的胜肽与低聚核苷酸药物形式等主题进行议论。本论坛为时一天,各种专业领域的人齐聚一堂,探讨转译研究的课题,针对本领域潜在商业机会交换意见,不但是独一无二的活动,协助研究罕见疾病的研究人员与专业技术人员,和赞助商企业干部交换意见、建立合作关系也是重要的目的之一。

Who should attend: Scientists, Lab Managers, Clinicians, Team Leads, Directors and Executives from Pharma, Biotech, Academia, Government, Contract Research Labs and Technology Providers involved in Drug Discovery & Development, Functional Screening, Target Identification and Validation, Biomarker Discovery, Translational and Clinical Research, Bioinformatics, Diagnostics, Alliance Management, and other areas important to Rare Diseases.

Topics will include, but are not limited to:

  • Update on peptide and oligonucleotide drugs for treating rare diseases
  • Evaluating new models and approaches to identify novel drug targets and biologic modalities
  • Using CRISPR, stem cells, and other innovative tools for understanding and treating rare diseases
  • Finding computational and bioinformatics tools for identifying disease pathways and drug targets
  • Exploiting proteomics, genomics, and metabolomics tools for drug and target discovery
  • Exploring gene therapy, cell therapy, and gene editing

The deadline for submission is September 15, 2017.

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

* 活动内容有可能不事先告知作更动及调整。